Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;5(9):520-8.
doi: 10.1038/nrneph.2009.114. Epub 2009 Jul 28.

Impact of treating the metabolic syndrome on chronic kidney disease

Affiliations
Review

Impact of treating the metabolic syndrome on chronic kidney disease

Varun Agrawal et al. Nat Rev Nephrol. 2009 Sep.

Abstract

The metabolic syndrome is defined by the concurrent presence of at least three metabolic disorders that are associated with an increased risk of cardiovascular disease and diabetes. Results from prospective and cross-sectional studies also point to an association between the metabolic syndrome and chronic kidney disease. Visceral obesity and insulin resistance are two important features of the metabolic syndrome that might explain renal injury. We reviewed the literature to examine whether treatment of the metabolic syndrome can favorably influence renal outcomes. Weight loss, regular exercise, and a low-calorie, low-fat diet are first-line treatments of the metabolic syndrome, yet few data are available to indicate that such lifestyle interventions can prevent or reverse renal damage. Similarly, results from few studies show little or no beneficial effect of blood pressure control, use of statins, fibrates, thiazolidinediones or metformin on renal parameters in patients with metabolic syndrome. The reasons for the lack of trials in this research field are also discussed. This Review identifies the need to improve understanding of the role of metabolic syndrome in chronic kidney disease, define consistent criteria for metabolic syndrome and perform clinical trials that analyze renal outcomes as primary end points.

PubMed Disclaimer

References

    1. J Am Soc Nephrol. 2004 Nov;15(11):2792-800 - PubMed
    1. Kidney Int Suppl. 1999 Jul;71:S51-3 - PubMed
    1. J Am Coll Cardiol. 2008 Oct 7;52(15):1201-10 - PubMed
    1. Int J Obes (Lond). 2005 Apr;29(4):436-42 - PubMed
    1. Fertil Steril. 2008 May;89(5):1221-1228 - PubMed

MeSH terms

Substances